Rani Therapeutics Stock (NASDAQ:RANI)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$1.47

52W Range

$0.39 - $3.87

50D Avg

$1.55

200D Avg

$0.98

Market Cap

$98.18M

Avg Vol (3M)

$18.23M

Beta

0.42

Div Yield

RANI Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

105

IPO Date

Jul 30, 2021

Website

RANI Performance

RANI Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-53.31M	$-66.10M	$-63.45M
Net Income	$-30.02M	$-33.97M	$-63.34M
EBITDA	$-53.31M	$-65.28M	$-60.89M
Basic EPS	$-1.05	$-1.33	$-2.66
Diluted EPS	$-1.05	$-1.33	$-2.66

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Mar 31, 25 | 4:30 PM

Q4 23Mar 20, 24 | 4:30 PM

Q4 22Mar 22, 23 | 4:30 PM

Peer Comparison

Ticker	Company
MIST	Milestone Pharmaceuticals Inc.
CRBP	Corbus Pharmaceuticals Holdings, Inc.
MOLN	Molecular Partners AG
TNXP	Tonix Pharmaceuticals Holding Corp.
SGMO	Sangamo Therapeutics, Inc.
CRDF	Cardiff Oncology, Inc.
APLT	Applied Therapeutics, Inc.
IPHA	Innate Pharma S.A.
ELTX	Elicio Therapeutics, Inc.